2-(p-Toluyl)-4-iodmethyloxazol | 33162-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(p-Toluyl)-4-iodmethyloxazol
• 英文别名: 4-iodomethyl-2-p-tolyl-oxazole；4-(Iodomethyl)-2-(4-methylphenyl)-1,3-oxazole
• CAS: 33162-09-3
• 化学式: C₁₁H₁₀INO
• 分子量: 299.111
• InChiKey: VBEYNUQRWAKFMV-UHFFFAOYSA-N

物化性质

• 沸点：
  364.8±52.0 °C(Predicted)
• 密度：
  1.642±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(chloromethyl)-2-(p-tolyl)oxazole 在 potassium iodide 作用下， 以 乙醇 为溶剂， 生成 2-(p-Toluyl)-4-iodmethyloxazol
  参考文献：
  名称：

  2-芳基-4-氯甲基-恶唑Mitt.杂环化合物中的Delepine反应

  摘要：

  借助Hantzsch反应制备了许多2-芳基-4-氯甲基恶唑，同时使用Delépine反应获得相应的氨甲基衍生物。

  DOI：

  10.1002/ardp.19713040608

文献信息

• Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20040122069A1

  公开（公告）日：2004-06-24

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披露了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。这些化合物包括式I,1中定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物通常具有降脂和/或三酸甘油酯降低作用，并且适用于例如治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。
• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209920A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  芳基环烷基取代的烷基酸衍生物，其制备方法及其作为药物的用途。该发明涉及芳基环烷基取代的烷基酸衍生物及其生理可接受的盐和生理功能衍生物。所描述的化合物为式I，其中基团如所定义，以及其生理可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍、葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Stapper Christian

  公开号：US20080167354A1

  公开（公告）日：2008-07-10

  The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  该发明涉及芳基环烷基取代的脂肪酸衍生物及其生理上可接受的盐和生理功能衍生物。所描述的是公式I中的化合物，其中基团如定义的那样，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗有关的疾病。
• DIARYLCYCLOALKYLDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS PPAR-AKTIVATOREN
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1425014A1

  公开（公告）日：2004-06-09